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A new class of platinum(II) complexes with the
phosphine ligand pta which show potent
anticancer activity†
M. D. Živković,a J. Kljun,b T. Ilic-Tomic,c A. Pavic,c A. Veselinović,d D. D. Manojlović,e
J. Nikodinovic-Runic*c and I. Turel *b
The anticancer potential of sixteen platinum(II) complexes with general formulae [PtCl(hq)(S-dmso)]
(1a–8a) and [PtCl(hq)(pta)] (1b–8b) (where hq is 5-chloro-7-iodo-8-quinolinol (clioquinol; cqH) (1a, 1b),
8-hydroxy-5-nitroquinoline (nitroxoline; nxH) (2a, 2b), 5,7-dichloro-8-quinolinol (3a, 3b), 5,7-diiodo-8-
quinolinol (4a, 4b), 5,7-dibromo-8-quinolinol (5a, 5b), 5,7-dichloro-8-hydroxy-2-methyl-quinoline (6a,
6b), 8-hydroxyquinoline (7a, 7b) and 8-quinolinethiol (8a, 8b); dmso is dimethyl sulfoxide and pta is 1,3,5-
triaza-7-phosphaadamantane) was determined through in vitro cytotoxicity assay in human fibroblasts
(MRC5) and two carcinoma cell lines (A375 and A549) and embryotoxicity assay in a zebrafish model.
Interactions with double stranded DNA through in vitro assay and a molecular docking study were exam-
ined. All complexes, except 6a, exhibited a high cytotoxic effect on MRC5 cells at a concentration of
10 µg mL−1 while 1b, 5a, 6a and 3b showed selective toxicity towards carcinoma cell lines. In general,
pta-based complexes (series b) were more toxic according to the results of a MTT screen and the LC50
values obtained in zebrafish (Danio rerio) assay; they also induced higher oxidative stress in this model.
Successful cellular uptake of complexes was shown by the ICP-MS methodology. The binding propensity
of the complex with DNA obtained in in silico studies can be correlated with those from the experimental
investigation. Compounds with the highest binding potential, according to the interaction energy value,
were 1b, 3b, 6b and 5b. From observations of the DNA interaction ability and of the in silico assessment,
no apparent DNA fragmentation was observed either on DNA extracted from the treated cancer cell line
or from the zebrafish embryos.
Introduction
The development of metallodrugs and the study of their mode-
of-action has become one of the most important fields of in-
organic chemistry after the discovery of cisplatin and its anti-
tumor activity in the 1960s.1 Cisplatin and its successors are the
most often used metal-based drugs in cancer chemotherapy.2,3
The high general toxicity of cisplatin which induces severe
side-effects, such as nephrotoxicity, neurotoxicity, ototoxicity,
and emetogenesis,4 necessitates the development of novel anti-
tumor metal-based therapeutic agents. Besides problems with
their toxicity, another limitation of the clinical efficacy of plati-
num drugs is their ability to induce cellular resistance.5–7
Resistance to cisplatin is generally multifactorial and can be
attributed to reduced drug accumulation, inactivation of drugs
by interaction with thiol containing species, and changes in
the proteins involved in apoptosis.8–10 Carboplatin and oxali-
platin, the second generation of platinum-based drugs, were
developed to obtain better antitumor activity, increased solubi-
lity and lower toxic side effects compared to cisplatin.8,9 The
interactions which are responsible for antitumor activity of Pt-
based drugs are covalent binding to guanine N7 atoms or
intercalation of aromatic ligands into cellular DNA. The result-
ing changes in the tertiary structure of DNA lead to cancer cell
death through apoptosis.10–12 Despite all these drawbacks, the
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first-line chemotherapy for 12 different neoplasms with more
than 50% of clinically applied anticancer regimens contains a
platinum(II)-based compound.13–15
Considering all the mentioned facts, our idea was to design
new Pt-based anticancer compounds containing ligands which
already exert biological properties expecting synergistic
effects.16 Several 8-hydroxyquinolines (hqH) are already known
for their antimicrobial and antiprotozoal activity and many of
them are or were used in clinical practice. Their biological
activity is often ascribed to their ability to bind di- and triva-
lent transition metal ions such as copper(II), zinc(II), and iron(III).
The hydroxyquinolines are known to be proteasome and
NFκB inhibitors, inducers of apoptosis of human cancer cell
lines, and stimulators of macrophages to release tumour
necrosis factor alpha as well as potential therapeutic agents in
the treatment of Alzheimer’s and Huntington’s diseases.16
Clioquinol (5-chloro-7-iodo-8-hydroxyquinoline; cqH; Fig. 1) is
a member of the family of 5,7-(di)halo substituted hqH, for-
merly antibacterial agents but now used mainly as antiseptics
or disinfectants. It has been shown that clioquinol activity is
copper dependent and that it induces cell death in leukaemia
and myeloma cell lines through the inhibition of the
proteasome.17–20
Interestingly, at non-cytotoxic concentrations the inhibitor
impairs the degradation of the extracellular matrix and
tumour cell invasion, revealing a specific anti-cancer mechan-
ism not related to a general compound-induced cytotoxicity.21
Another member of the 8-hydroxyquinoline family already
used in medicinal practice is nitroxoline (5-nitro-8-hydroxy-
quinoline, nxH; Fig. 1). This drug is an antibacterial agent
used in the treatment of acute or recurrent urinary tract infec-
tions. Nitroxoline also showed appreciable bactericidal activity
against growing and/or dormant tubercle bacilli.19,22 Also, it
was discovered that nitroxoline is a potential selective and
reversible inhibitor of cathepsin B which results in in vitro and
in vivo tumor progression.23–25 The activity of nitroxoline was
explained by the inhibition of extracellular and intracellular
degradation of the extracellular matrix (ECM), reducing tumor
cell spreading. These facts suggest that nitroxoline has great
potential as a drug candidate in the treatment of cancer and
other diseases connected with increased cathepsin B
activity.23–25
On the other hand, the chemistry of second-row transition-
metal complexes of 1,3,5-triaza-7-phosphaadamantane (pta)
and related ligands has attracted much attention due to their
potential as water-soluble catalysts.26,27 These complexes show
high stability due to the strong metal–phosphorus bond. The
ligand pta has become prominent in the bioinorganic scientific
community as a ligand in the ruthenium–arene-pta (RAPTA)
class of compounds developed by Dyson’s group. Among
the hundreds of reported compounds of this class, several
compounds have achieved great success at the preclinical
development stage as potential antimetastatic agents, thermo-
responsive anticancer drugs and as agents for targeted cancer
therapy targeting thiol and selenol containing proteins.27 The
coordination chemistry of other precious metal–pta complexes
is very well developed as numerous other rhodium, osmium
and iridium organometallic compounds as well as rhodium
and gold coordination compounds have been investigated for
their catalytic and medicinal properties. Interestingly, reports
of palladium and platinum are relatively scarce and in the case
of platinum, complexes almost exclusively contain structures
of bis-pta complexes (or complexes bearing one pta and
another phosphine ligand).28,29 Some of these compounds
were evaluated as potential medicinal agents; however, these
studies had limited scope because of the very low aqueous
solubility of these compounds.
In the current study we have continued this line of research,
focusing on the synthesis, characterization and biological
evaluation of the series of [PtCl(hq)(S-dmso)] type complexes,
as well as their pta analogs [PtCl(hq)(pta)], all of them
differing in the bidentate ligand with the quinoline moiety.
Cytotoxicity against human cell lines and embryotoxicity in a
zebrafish model were evaluated. The cellular Pt content was
monitored by means of ICP-MS. The DNA-interaction ability of
the selected complexes in silico and DNA fragmentation pat-
terns of the treated cells were examined. The in silico DNA
binding affinities of the studied complexes were obtained on
the basis of a molecular docking study.
Results and discussion
Synthesis and characterization of 8-hydroxyquinoline Pt(II)
complexes
Sixteen Pt(II) complexes with general formulae [PtCl(hq)
(S-dmso)] (1a–8a) and [PtCl(hq)(pta)] (1b–8b) (where hq is
5-chloro-7-iodo-8-quinolinol (clioquinol; cqH) (1a, 1b),
8-hydroxy-5-nitroquinoline (nitroxoline; nxH) (2a, 2b), 5,7-
dichloro-8-quinolinol (3a, 3b), 5,7-diiodo-8-quinolinol (4a, 4b),
5,7-dibromo-8-quinolinol (5a, 5b), 5,7-dichloro-8-hydroxy-2-
methyl-quinoline (6a, 6b), 8-hydroxyquinoline (7a, 7b) and
8-quinolinethiol (8a, 8b); dmso is dimethyl sulfoxide and pta
is 1,3,5-triaza-7-phosphaadamantane) have been synthesized
(Fig. 2). The structures of all Pt(II) complexes were confirmed
by elemental microanalyses, ESI-HRMS, NMR (1H and 31P), IR
and UV-vis spectroscopy. Spectroscopic data of these com-
plexes were correlated with those previously reported for 1a,
3a, 4a, 5a, 7a and 8a.16,30–32 Due to the low solubility of these
complexes in deuterated solvents 13C NMR spectra were not
recorded. The crystal structures of complexes α-2a, β-2a, β-6a,
Fig. 1 The clinically used 8-hydroxyquinoline agents clioquinol and
nitroxoline.
Research Article Inorganic Chemistry Frontiers
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β-1b, and β-4b (see the definition of α and β isomers in
Table 1) were confirmed by X-ray single crystal diffraction
analysis.
The reaction pathway for the preparation of complexes
1a–8a and 1b–8b is shown in Scheme 1. The platinum(II) com-
plexes 1a–8a were obtained by reacting the platinum precursor
[PtCl2(dmso)2] with 1.05 molar equivalents of the corres-
ponding ligand hqH by addition of 1.2 equivalents of sodium
methoxide as a base. All these reactions were performed in a
1 : 2 methanol/acetone mixture. The solutions were filtered
through Celite and the complexes were isolated as yellow
solids after the evaporation of the solvents. The purity of the
obtained complexes was above 98% and as such was suitable
for further biological evaluation. Crystals of 6a were obtained
by slow evaporation of the 1 : 2 methanol/acetone solvent
mixture.
An exception was complex 2a, where the synthesis resulted
in a mixture of regioisomers in a α : β ratio of 5 : 1 as evidenced
by the 1H NMR spectrum (Fig. S1†). Attempts to synthesize or
isolate each isomer by column chromatography on silica or
alumina were not successful. Nevertheless, both isomers crys-
talized from a methanol/dichloromethane (DCM) solution
where the major product was α-2a isomer crystallized as big
Fig. 2 Structural representation of the investigated Pt(II) complexes
(X is S-dmso for 1a–8a and pta for 1b–8b; dmso is dimethyl sulfoxide
and pta is 1,3,5-triaza-7-phosphaadamantane). Scheme 1 Schematic representation of the reactions for the synthesis
of 1a–8a and 1b–8b.
Table 1 Relative energies (kcal mol−1) of complexes 1a–8a and 1b–8b for α and β conformations obtained at the semi-empirical level of theory and
PM6 calculations using a composite basis set
[PtCl(hq)(S-dmso)] complex Isomer Relative energy (kcal mol−1) [PtCl(hq)(pta)] complex Isomer Relative energy (kcal mol−1)
1a α 15.9387 1b α 42.7315
β 0.0a β 0.0i
2a α 0.0b 2b α 42.9091
β 23.2072 β 0.0j
3a α 58.0942 3b α 42.5878
β 0.0c β 0.0k
4a α 56.8756 4b α 41.5913
β 0.0d β 0.0l
5a α 56.5951 5b α 41.2826
β 0.0e β 0.0m
6a α 128.8302 6b α 142.4817
β 0.0f β 0.0n
7a α 53.9608 7b α 38.5925
β 0.0g β 0.0o
8a α 119.4878 8b α 106.2298
β 0.0h β 0.0p
N.B.: The substitution of the S-coordinated dmso for the P-coordinated pta and the exchange of the N,O-ligands 1–7 for the N,S-ligand 8 mean
that compounds which are structural analogs have different (even opposite) configuration indices. In order to facilitate the visualization we have
defined the isomers as isomers α and β. The exact nomenclature according to IUPAC recommendations was added to the ESI (Table S1). Absolute
energy baselines (in hartree): a −0.03878; b 0.027597; c −0.07739; d 0.00054; e −0.04089; f −0.09277; g −0.05503; h −0.00169; i 0.031101; j 0.005383;
k −0.00719; l 0.070383; m 0.029125; n −0.02058; o 0.015464; p 0.069494.
Inorganic Chemistry Frontiers Research Article
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yellow prismatic crystals while the minor β-2a product crystal-
lized as much smaller and thin orange needle-like crystals.
Since we observed the presence of two geometric isomers of
compound 2a, we searched the Cambridge Structural Database
(CSD) for structural data of chemically related compounds
with the fragment [PtCl(hq)]. At present (data retrieved on
11.4.2017), the database contains only six crystal structures of
five different compounds containing this structural fragment.
Complex 7a reported by Meng et al.32 adopts the α confor-
mation, complex 4a also reported by Meng et al. is a co-crystal
of both regioisomers (though the authors might not have
noticed it, as this fact is not addressed in the paper at all),
Kato et al. reported the structure of the complex (8-hqHH)
[Pt(hq)Cl2], which is not relevant for regioisomer discussion,
33
the papers of Ferraz et al.30 and Santos et al.16 both report the
crystal structure of α-1a, and finally Yue et al. report the crystal
structure of [PtCl(2-methyl-8-hydroxyquinolinato)(S-tetra-
hydrothiophene) which adopts the β conformation. Intrigued
by the inconsistencies between the reported crystal structures
as well as our own results and since we were unable to obtain
crystals suitable for X-ray structural analysis of all novel com-
pounds, we complemented spectroscopic and structural data
with calculations of relative energies for α and β forms of com-
plexes (Table 1) in order to unequivocally determine the struc-
tures of compounds. Complexes in which the oxygen/sulfur
atom from the hq− ligand is at trans position relative to the
chloride atom coordinated to the Pt(II) ion (β isomer; Table 1)
were calculated to be lower in energy than the corresponding α
isomer with the exception of 2a complex. These results suggest
that the β isomer is energetically preferred, which well mirrors
the experimentally observed structures in the reactions of com-
plexation. On the other hand, the energy of the β form of 2a is
higher than that of α, indicating that in this case α mode of
coordination is energetically favorable (Table 1), though the
energetic difference between the two isomers is the smallest in
this case and can thus account for the concomitant presence
of both isomers in solution.
Drawing definite conclusions is in this case very difficult
and ours are supported by the following facts. Firstly, the crys-
tals in the previous reports were obtained directly from the
reaction mixtures,32 by attempting to crystallize a different
complex from a dmso solution,30 or the crystallization con-
ditions are not reported,16 while in our case pure isolated com-
pounds (except 2a) were used for crystallization experiments.
Secondly, based on our computational study, the experimental
observation of both isomers in varying ratios in crude reaction
mixtures and our structural studies, we could conclude that
the reported crystal structures of α isomers are the result of
crystallizations of minor regioisomers.
Complexes 1b–8b were obtained from the corresponding
complexes 1a–8a in reactions with one molar equivalent of the
pta ligand in chloroform. The reaction mixtures were heated
for 1 h and then stirred at room temperature for the next 24 h,
in order to obtain better yield and purity of the products, as
prolonged heating resulted in increased amounts of side-
products. Purifications of these complexes were performed on
chromatographic columns with alumina as the stationary
phase and acetone/DCM in different ratios as eluents. The
column was first eluted with 3% acetone/DCM to remove the
excess of the hq ligand, which was followed by elution with
20% acetone/DCM in which Rf factors of all complexes are in
the range 0.65–0.80 while the starting [PtCl2(hq)(dmso)], as a
common impurity present in all syntheses, has an Rf factor of
0.30–0.40. The solvents were rotary evaporated and we have
tried to obtain crystals from solid residues. A mixture of DCM,
in which the compounds are well soluble, and the nonpolar
solvent n-hexane (the solvent mixture ratio was approximately
3 : 1) was used for crystallization (Fig. 3).
All the investigated Pt(II) complexes have a square-planar
geometry with the bidentately coordinated hq ligand. The
complexes adopt a slightly distorted square-planar geometry as
evidenced by the τ4 and τ′4 square-planar geometry indices
(Table 2). There are no strong supramolecular interactions to
explain the distortion which is most likely due to the steric
bulk of the S-dmso and pta ligands in which the coordinated
S and P atoms have tetrahedral geometry. To further support
this explanation, the distortion is most notable in the case of
compound 6a, bearing the only hydroxyquinoline ligand with
a substituent at position 2 (methyl). The observed bond
lengths and angles fall within the common range of values.
Interestingly, complex 6a crystallizes with three crystallographi-
cally independent complex molecules with one co-crystallized
solvent molecule (acetone), a phenomenon quite rarely
observed (Fig. S2†). The chemical shifts of the aromatic
protons of the ligands (7.19–9.65 ppm) are mostly shifted
Fig. 3 Crystal structures of complexes: top – α-2a, β-2a; middle –
β-6a; bottom – β-1b and β-4b with heteroatom labelling. Thermal ellip-
soids are shown at the 30% probability level. Hydrogen atoms are
omitted for better clarity of presentation. For complex β-6a only one of
the three crystallographically independent complex molecules is shown
(for all three, see Fig. S2).
Research Article Inorganic Chemistry Frontiers
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upfield upon bidentate coordination of hq oxygen and nitro-
gen atoms to Pt(II) (7.11–9.11 ppm). The singlet at 2.62 ppm
for the methyl protons of free dmso was shifted downfield
(3.55–3.67 ppm) after its coordination to the Pt(II) species in
1a–8a. Monodentate coordination of the pta ligand through
the phosphorus atom in 1b–8b was detected by the appearance
of the resonance in the region 4.40–4.48 ppm which belongs to
the N–CH2–P methylene protons. This resonance is at
4.06 ppm for the free pta ligand. Correspondingly, in the 31P
NMR spectrum of 1b–8b complexes, a single resonance peak at
δ −97.4 ppm for the free pta ligand is shifted downfield to the
region −64.10 to −61.41 ppm upon coordination of the pta
ligand through the phosphorus atom.
Since dmso, a commonly used co-solvent in biological
assays, is known to have deleterious effects on clinically used
platinum agents such as cisplatin,36 we monitored the stability
of complexes 1b and 4a in dmso solution over a period of
7 days by 1H NMR. The samples were kept at room temperature
and in the dark between measurements. No changes in the
NMR spectra of the studied complexes were observed
(Fig. S3†). Considering this, we concluded that all the investi-
gated Pt(II) complexes are stable in this solvent in the time-
frame of the biological experiments and are suitable for
further investigations.
Cell viability and uptake assays
The antiproliferative (cytotoxic) potentials of all sixteen Pt(II)
complexes as well as cisplatin (Cis) were screened on human
lung fibroblasts (MRC5) and melanoma (A375) by MTT assay
after 48 h treatment (Fig. 4). All complexes, except 6a, exhibi-
ted a high cytotoxic effect on MRC5 cells at a concentration of
10 µg mL−1 (Fig. 4A). 3a, 2b, 6b, 8a, 8b and Cis caused 10–40%
cell death at a concentration of 5 µg mL−1 on this model of
normal cell lines (Fig. 4A). Generally, the tested compounds
exhibited similar profiles of antiproliferative activity against
the melanoma cell line (Fig. 4B), with 1b, 5a, 6a and 3b
showing a certain selectivity towards the carcinoma cell line.
In general, pta-derivatives appeared to be more cytotoxic. This
is in line with previous observations that transition-metal com-
plexes containing one or more pta ligands had improved
aqueous solubility and therefore greater biological activity.28,29
Based on this initial screen considering selectivity towards
cancer cells, four pairs of complexes were selected for further
evaluation of the anticancer potential, making sure that both
dmso- and pta-counterparts were included. IC50 values were
determined against MRC5, A375 (melanoma) and human lung
cancer (A549) by MTT assay (Table 3). Generally, the selected
compounds showed a selectivity index comparable to cisplatin,
but 1b, 5b, and 6a had IC50 values 2–2.5-fold higher against
cancer cell lines (Table 3). 5b (5,7-dibromo-8-quinolinol-pta),
3b (5,7-dichloro-8-quinolinol-pta) and 1a (5-chloro-7-iodo-8-
quinolinol-dmso) were the most cytotoxic, with IC50 values
comparable to that of cisplatin. These three complexes and
their corresponding counterparts were used in uptake experi-
ments to ensure their ability to enter the cells and to compare
it to that of cisplatin (Fig. 5).
Table 3 In vitro antiproliferative activity given as IC50 ± SD in µM of
Pt(II) complexes and of cisplatin
Compound
Cell lines
MRC5 A375 A549
1a 3.2 ± 0.1 4.1 ± 0.1 2.5 ± 0.1
1b 7.2 ± 0.2 2.9 ± 0.1 4.3 ± 0.2
3a 13.4 ± 0.4 11.5 ± 0.3 11.5 ± 0.3
3b 4.2 ± 0.2 3.3 ± 0.1 2.5 ± 0.1
5a 6.5 ± 0.3 4.1 ± 0.1 7.4 ± 0.4
5b 3.6 ± 0.1 2.9 ± 0.1 1.5 ± 0.1
6a 18.7 ± 0.5 9.3 ± 0.3 8.4 ± 0.5
6b 12.2 ± 0.4 12.2 ± 0.5 9.8 ± 0.3
Cis 3.3 ± 0.1 4.1 ± 0.2 2.5 ± 0.1
Fig. 4 In vitro cytotoxicity (antiproliferative effect) profile of Pt(II) com-
plexes (1–8a/b) and cisplatin (Cis) against: (A) human lung fibroblast
(MRC5) and (B) melanoma (A375) cell lines (□, 0.1 µg mL−1; , 1 µg mL−1;
, 5 µg mL−1 and ■, 10 µg mL−1 concentration of the tested compound).
Table 2 Selected bond lengths (Å) and 4-coordinate geometry indexes
τ4 and τ4’
Cpd Pt-N Pt-O Pt-Cl Pt-S τ4
34 τ′4
35
α-2a 2.028(3) 2.017(3) 2.294(1) 2.207(1) 0.091 0.115
β-2a 2.052(7) 2.031(7) 2.278(3) 2.207(2) 0.076 0.089
6a A 2.105(3) 1.996(2) 2.306(1) 2.224(1) 0.139 0.171
B 2.089(3) 1.999(2) 2.300(1) 2.214(1) 0.118 0.137
C 2.088(3) 1.995(3) 2.302(2) 2.206(1) 0.112 0.120
Cpd Pt-N Pt-O Pt-Cl Pt-P τ4 τ′4
1b 2.063(4) 2.010(3) 2.308(2) 2.198(2) 0.070 0.089
4b 2.079(5) 2.007(4) 2.298(2) 2.198(2) 0.066 0.083
τ4 = [360° − (α + β)]/(360° − 2·θ); τ4′ = [(β − α)/(360° − θ)] + [(180° − β)/
(360° − θ)]; α and β are the two greatest valence angles of the coordi-
nation center, θ is a tetrahedral angle of 109.471°. For the ideal square-
planar geometry τ4 and τ′4 values are 0, and for the ideal tetrahedral
geometry τ4 and τ′4 values are 1.
Inorganic Chemistry Frontiers Research Article
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In these experiments, 2 µM cisplatin and selected Pt(II)
complexes were used since this concentration is close to IC50
values for Cis, 1a, 3b and 5b (Table 3). Upon exposure to 2 µM
solutions for 2 h, the cellular content of Pt metal substantially
increased in comparison with the cells that were treated with
the vehicle solvent (dmso) that had Pt content close to zero.
Therefore, facile uptake of both Cis and Pt(II) complexes
occurred within 2 h of exposure (Fig. 5). Notably, all the tested
complexes showed an increased ability to internalize in com-
parison with Cis, especially 3a, that had the highest IC50 value
of 11.5 µM and showed the best uptake, suggesting that the
activity of the compounds only partially depends on the ability
to enter the cells. Complexes containing a bulkier pta-ligand
(b series) were less readily taken up by cells in comparison
with dmso-based complexes, with the exception of 1b (Fig. 5).
A recent study also showed successful cellular uptake and
equal distribution between the nucleus and mitochondria of
4a (5,7-diiodo-8-hydroxyquinoline complex) in HepG2 cells.32
Previously, the investigation of a series of four platinum(II)
complexes with 8-hydroxyquinoline derivatives, including 1a,
3a and 7a, showed that cytotoxic activity for several tumor cell
lines – HBL-100 (breast), HeLa (cervix), SW1573 (non-small cell
lung carcinoma) and WiDr (colon carcinoma) – strongly
depends on the substituents on the quinoline ring.16 Thus, in
the case of the HLB-100, SW1573 and WiDr cell lines, a high
biological activity was obtained for 8-hydroxyquinoline com-
plexes with hydrogen or iodine at position 7, while the chlor-
ine atom at the same position reduces the cytotoxicity.
However, the HeLa cell line showed a different response where
the substitution at position 7 of 8-hydroxyquinoline by a chlo-
rine atom increases the cytotoxic activity of the platinum
complex. The complex with the non-substituted 8-hydroxyqui-
noline was the most active in all the tested cell lines.16
Moreover, the effect of iodine substitution was studied in the
case of complexes 7a and 4a (hq ligand and diiodo substituted
analog, respectively). The inclusion of iodine caused an
increase in cytotoxicity with a decrease of IC50 values from
9–30 µM to 4–12 µM (by a factor of 1.8–4.3) in five selected
human cancer cell lines (BEL-7404, hepatoma; HepG2, liver;
NCI-H460, lung; T-24, bladder carcinoma, A549, lung carci-
noma) while retaining the same toxicity level on normal liver
cells HL-7702 (IC50 = 25 µM). The most sensitive of the tested
cell lines, HepG2 was subjected to cell cycle analysis which
showed cell cycle arrest in the S phase with higher S phase
arrest for the iodo-substituted compound. This was supported
by the down-regulation of cdc25A, cyclin B, cyclin A, and CDK2
and the up-regulation of p53, p27, and p21, which was deter-
mined by the western blot assay. Complex 4a also acted as a
telomerase inhibitor by interacting with G-quadruplexes and
triggering cell senescence and apoptosis. Mitochondrial dys-
function was also observed in the treated cells, which might
suggest an induction of mitochondrion-mediated apoptotic
pathways, a mechanism not unknown for platinum-based
agents.37 Moreover, the inclusion of iodine improved cellular
uptake of Pt species and the authors suggest that halogenation
of selected scaffolds in metal-based drug design is an interest-
ing strategy.
In line with a previous study,16 we have confirmed that 1a
(8-hydroxyquinoline complexes with chlorine at position 5 and
iodine at position 7) was the most potent in terms of IC50
values. In addition, the pta-based complex (1b) showed similar
activity; however, the selectivity of both complexes was quite
poor (Table 3). Furthermore, the lung cancer cell line again
appeared to be more sensitive in comparison with melanoma,
like SW1573 in the previous study in comparison with breast
and cervical cancer cells. The obtained results showed that the
substitution pattern had an important effect on the antiproli-
ferative activity and selectivity of the complexes depending on
the cell line.
Interactions of Pt(II) complexes with DNA
It was established that Pt(II) complexes bind to DNA via coordi-
nation bonds distorting the normal three-dimensional struc-
ture of the double helix.38,39 This subsequently induces cell
death through apoptosis.40 Given that DNA is often the
primary target of Pt(II)-based antitumour complexes,41 we have
investigated the reactivity of complexes 1a and 1b with the
model compound 5′-GMP by 1H NMR: the ability of Pt(II) com-
plexes 1–8 to interact with double stranded high molecular
weight DNA was investigated in vitro (Fig. 6A) and assessed
in silico (Fig. 6B).
As evidenced by 1H NMR experiments both 1a and 1b form
adducts with 5′-GMP within a few hours as we observe a
second set of signals assigned to 5′-GMP. However, the relative
ratio of this set of signals compared to the free 5′-GMP
decreases significantly within 24 hours with free 5′-GMP
signals again becoming predominant after 72 hours in the
case of 1a (Fig. S4†). In the case of 1b (Fig. S5†) the second set
of 5′-GMP signals remains minor throughout the experiment;
however, a third set of hydroxyquinoline signals is observed
which becomes predominant after 24 h. Due to the known
aqueous chemistry of platinum(II) coordination compounds
and the recent discoveries of the combined solvolytic effect of
dmso and water42 it is safe to assume that the chlorido and
the 5′-GMP ligands are released and a stable aqua or S-dmso
adduct is formed. As such, this weak interaction might not
prove significant in more complex biological systems in the
Fig. 5 Platinum content in A549 cells. Cells were treated with 2 µM cis-
platin (Cis) and selected complexes for 2 h at 37 °C. Data are shown as
mean values ± standard deviations.
Research Article Inorganic Chemistry Frontiers
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presence of other ligands with potentially higher affinity for
metal ions (inorganic anions, amino acid residues, etc.).
Electrophoresis patterns in the presence of 25 µg mL−1 con-
centration of Pt(II) complexes showed that most of the com-
plexes did not have the ability to interact with DNA in vitro in
aqueous solution at physiological pH 7.4 (Fig. 6A). This was
somewhat surprising due to the fact that an 8-hydroxyquino-
line conjugated system is expected to bind DNA via intercala-
tion. Only complex 6a showed similar interaction to that of cis-
platin, while 1b exhibited a slight ability to interact with DNA
(approx. 10% in comparison with the dmso control). It is
worth mentioning that complexes 8a and 8b could not be
included in this experiment due to their differing spectral
characteristics that may have caused the interference with the
signal (Fig. S6†).
In vitro DNA interaction pattern results may imply that com-
plexes 1b and especially 6a could exhibit irreversible DNA
degradation which may lead to cell death by necrosis, therefore
indicating a potentially higher general toxicity of these com-
pounds. However, both compounds exhibited lower antiproli-
ferative activities in cytotoxicity assays in comparison with cis-
platin (Table 3). On the other side, complexes 5b and 3b
showed comparable and better cytotoxicity profiles in compari-
son with cisplatin, and no apparent DNA interaction ability.
From the interaction with high molecular weight double
stranded DNA in vitro, cytotoxicity against human cell lines
could not be predicted, nor could DNA as a cellular target be
completely excluded. Therefore, we examined the DNA-inter-
action ability of the selected complexes in silico and DNA frag-
mentation pattern of the treated A549 cells, as well as zebrafish
embryos (Fig. S7†).
All information related to in silico DNA binding affinity for
the studied compounds was obtained using a molecular
docking study. The predicted top-ranking pose with the com-
plex’s lowest energy was used to suggest the best possible geo-
metry of compounds inside the DNA double helix and the
highest binding affinity of DNA. MolDock Score, Docking
Score, Rerank Score, van der Waals (VdW) and van der Waals
(Hbond) Score, Steric interactions, and Ligand efficiency (LE1
and LE3) were used as scoring functions. Top ranked poses
according to the used scoring functions are presented in
Table 4.
The more the negative value obtained from the applied
score function, the greater the binding propensity of the
complex with DNA, which can be correlated with the obtained
experimental values for anticancer activity. According to
Rerank Score, compounds with the highest binding potential
were 1b (−693.372 kcal mol−1), 3b (−687.718 kcal mol−1), 6b
(−687.666 kcal mol−1) and 5b (−656.663 kcal mol−1). The
obtained results for van der Waals interactions of complexes
with DNA revealed that among the studied complexes com-
pound 1b has the highest interaction energy (−652.659
kcal mol−1) followed by compounds 3b (−622.397 kcal mol−1)
and the lowest interaction was determined for compound 1a
(−129.067 kcal mol−1).
Hydrogen bonds formed between a complex and DNA are
important for metal complex–DNA binding and for other poss-
ible activities, such as antiviral or antibacterial.43 According to
DNA (Hbond) Score values, compounds with the highest inter-
action energy were 6b and 3b (−478.944 kcal mol−1 and
−473.265 kcal mol−1). Also docking studies determined that
compounds 1a, 3a and 6a didn’t form hydrogen bonds with DNA.
Therefore, it can be concluded that the obtained results are in
correlation with the presented experimental results for IC50
values (3b having IC50 values between 2.5 and 4.2 µM;
Table 3), but to a much lower extent with in vitro DNA inter-
Fig. 6 DNA interaction ability of Pt(II) complexes (A) 1–7a/b in compari-
son with cisplatin (Cis) and dmso control (M-λ-HinDIII high molecular
weight marker, Promega); and (B) computational docking model illus-
trating the interactions between compounds 1b, 3b and 5b and the
minor groove of DNA.
Inorganic Chemistry Frontiers Research Article
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action ability experiments, with 6a showing some interaction
(Fig. 6A).
The best poses for the selected complexes according to
in vitro and in silico studies in relation to their overall values for
interaction with DNA are presented in Fig. 6B. The minimum
energy docked pose revealed that all complexes are very well
fitted into the DNA minor groove. Docking poses suggest that
complexes and DNA base pairs are arranged in such a way that
they have effective π–π stacking interactions. These interactions
can lead to higher van der Waals interactions with the DNA
functional groups which define the stability of the groove,
making the AT regions more preferable regions of the dodeca-
mer.44 Complexes exhibited additional stabilization through
the strong intermolecular hydrogen bonding interaction
between the C-2 carbonyl oxygen of T and the N-3 nitrogen of
A. The best binding pose in the AT stretches of the minor
groove was indicative of an extensive H-bonding network.
Structural analysis of the docking positions gave insight into
the binding pattern of the complexes. According to the
obtained results for the preferable conformation of the
complex inside DNA, only the hydroxyquinoline (hq) part of
the complex interacted with DNA. This fact can be correlated
with the fact that the studied complexes had a different mech-
anism of action in comparison with cisplatin. Calculations
revealed that in most cases, preferable atoms from the studied
complex molecule’s ligands that interacted with DNA were
halogen atoms.
In accordance with observations on the DNA interaction
ability and from the in silico assessment, no apparent DNA
fragmentation was observed either on DNA extracted from the
treated cancer cell line or from the zebrafish embryos, while
cisplatin was shown to induce DNA damage under the same
conditions (Fig. S7†). Indeed, it is generally accepted that
binding of cisplatin to genomic DNA (gDNA) in the cell
nucleus is largely responsible for its antitumor properties. The
damage induced upon binding of cisplatin to gDNA interferes
with normal transcription and/or DNA replication mecha-
nisms, and eventually, these disruptions in DNA processing
trigger cytotoxic processes that lead to cell death.45 However, it
is known that cisplatin forms a large amount of adducts in
mitochondrial DNA lacking histones.46 In any event, previous
to cisplatin binding to genomic or mitochondrial DNA a loss
of chloride groups is required. The N7 atoms of guanine and
adenine located in the major groove of the double helix are the
most accessible and reactive nucleophilic sites for platinum
binding to DNA.47,48 In accordance with our observations,
Kemp and co-workers have reported that DNA binding experi-
ments have shown no significant differences in the DNA
adducts formed between many of the DNA intercalators.49,50
This suggests that all DNA adducts formed by the bidentately
coordinated platinum(II) family of metal complexes are simi-
larly cytotoxic and/or that DNA binding may not be the sole
mechanism that determines their cytotoxicity. Therefore, it
can be hypothesised that differing cellular uptake levels or
differing intracellular drug transport may determine how
much of each DNA intercalator reaches its target intact,
thereby affecting cytotoxicity.
Toxicity of Pt(II) complexes (1a, 1b, 3a, 3b, 5a and 5b) in
zebrafish embryos
The effects of complexes on development of Danio rerio
embryos were examined at concentrations close to IC50 values
determined in the cytotoxicity assessment (Table 3). The selec-
tion of the complexes to be tested in zebrafish embryo model
was based on the highest selectivity between MRC5 and the
cancer cells. We exposed 4 h old embryos to various concen-
trations of Pt(II)-complexes and the obtained results revealed
different toxicity profiles between pta-based and dmso-based
platinum complexes (Table 5). According to the LC50 values
obtained in zebrafish assay (Table 5) the tested complexes are
ranked by their embryotoxicity as follows: 3b > 5b > 1b > 1a >
5a > 3a, which clearly demonstrates higher toxicity of pta-
based complexes (series b) in comparison with dmso-based
complexes (series a), mirroring the results of the MTT screen
(Fig. 4). While dmso-based complexes had adverse effects on
embryo development at concentrations of 10 µg mL−1 (5a) and
≥5 µg mL−1 (1a) and had LC50 values higher than the IC50
values obtained in the cell lines assay, pta-based complexes
induced embryo mortality already at concentrations ≥1.5
µg mL−1 (1b and 3b) and ≥2 µg mL−1 (5b) (Fig. 7A) and showed
LC50 values comparable to those on cell lines. Interestingly,
complexes 1b and 3b induced similar defects in embryos such
as skeletal deformities and pericardial edema (Fig. 7B),
whereas 3b appeared to be more cardiotoxic than 1b, inducing
Table 4 Score values (kcal mol−1) for Pt(II) complexes
Cpd Hbond VdW E-Inter LE1 LE3 Pose energy Rerank MolDock
1a −5 −129.067 −98.269 −509.929 −333.842 −95.280 −630.430 −96.887
1b −478.944 −652.659 −123.771 −424.062 −277.349 −103.852 −693.372 −106.015
3a −5 −132.847 −100.705 −517.327 −342.509 −97.098 −650.766 −98.292
3b −473.265 −622.397 −123.413 −417.075 −275.087 −102.485 −687.718 −104.269
5a −205.606 −497.911 −94.029 −478.949 −287.765 −89.249 −546.753 −91.002
5b −142.906 −448.058 −116.990 −448.534 −262.665 −110.866 −656.663 −112.134
6a −5 −213.766 −103.317 −491.222 −281.537 −96.211 −563.073 −98.244
6b −49.584 −487.517 −130.261 −432.598 −264.487 −111.168 −687.666 −112.475
E-Inter – Inter-energy of pose. LE1 – Ligand efficiency calculated as MolDock Score divided by heavy atom count. LE3 – Ligand efficiency
calculated as Rerank Score divided by heavy atom count.
Research Article Inorganic Chemistry Frontiers
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slower embryo heart beat rate, absence of caudal circulation
and, consequently, higher pericardial edema. On the other
hand, complex 5b had a different milder teratogenic effect,
inducing only notochord deformity without effects on the
development of other organs (Fig. 7B).
Although cisplatin appeared to be nontoxic on developing
zebrafish embryos, treatments under 10 µg mL−1 cisplatin pre-
vented embryo hatching up to 120 hours post fertilization
(hpf) that is regarded as a toxicity parameter. Hatching
success is supposed to be a sensitive endpoint of the zebrafish
embryo in toxicity assay, since no hatched embryos had a
lethal outcome.51 While it has been demonstrated that plati-
num and platinum nanoparticles had an adverse impact on
the hatching success in developing zebrafish embryos,51,52 we
have recently shown that other Pt(II) complexes, such as
{[Pt(1,3-pd)Cl]2(µ-pz)}Cl2·2LiCl·2H2O, may adversely influence
zebrafish hatching as well.39 On the other hand, none of the
platinum(II)-complexes tested in this study interfered with
hatching success.
The most cytotoxic complexes (1a, 1b, 3a, 3b, 5a and 5b)
were also tested for the ability to induce the oxidative stress
response in zebrafish and to compare it to that of Cis (Fig. 8).
Reactive oxygen species (ROS) production at sublethal concen-
tration and concentration close to LC50 concentration values
(Table 5) was significantly higher in embryos treated with pta-
based complexes in comparison with that of dmso-based ones
(from 2.5-fold for 1a vs. 1b to 10-fold for 3a vs. 3b) and in com-
parison with Cis (Fig. 8B).
All three pta-based complexes markedly increased embryos’
ROS level at the IC50 values, thus indicating that this may be
one of the mechanisms of their activity. Notably, embryos
upon cisplatin treatment displayed an intensive fluorescence
in the region of caudal hematopoietic tissue at doses of
5 µg mL−1 and 10 µg mL−1 (Fig. 8A), indicating its possible
myelosuppressive effect. Dose-dependent myelosuppression,
particularly neutropenia, is one of the major side effects of cis-
platin therapy in cancer patients, restricting its therapeutic
use.53 On the other hand, none of the tested complexes (except
5b at 2.5 µg mL−1) increased ROS production in the caudal
hematopoietic tissue.
Cisplatin was approved by the Food and Drug
Administration in 1978 in spite of some dose limiting side
effects; hence data on cisplatin toxicology in wild type zebra-
fish that emerged as a model later is not readily available in
the literature. It was shown that 50 μM and 100 μM cisplatin
significantly reduced hair-cell survival up to 81% and 55%,
respectively, while at a concentration of 400 μM, cisplatin
induced a lethal outcome in embryos.54 It is noteworthy that
5b, which demonstrated preferential cytotoxicity against
Fig. 8 Effects of platinum(II) complexes (dmso-based: 1a, 3a and 5a in
comparison with pta-based: 1b, 3b and 5b) on ROS production in
zebrafish embryos (A) with the increased ROS production in the caudal
hematopoietic tissue marked by a dashed arrow. ROS levels were deter-
mined by measuring the fluorescence of individual zebrafish embryos
(B). Statistically significant differences between the control (0.1% DMSO)
and treated groups are denoted with asterisks (*P < 0.5, **P < 0.01;
***P < 0.001; Student’s t-test).
Table 5 In vivo toxicity response of zebrafish embryos. LC50 and EC50
values are given in µg mL−1
Compound LC50 (µg mL
−1) EC50 (µg mL
−1)
1a 3.53 3.73
1b 2.82 2.21
3a >10a >10a
3b 1.48 1.46
5a 8.92 6.89
5b 2.47 2.23
Cis >10a >10a
a 3a and cisplatin were nontoxic at the tested concentration range
(1–10 µg mL−1); LC50 – the concentration causing the mortality of 50%
of the zebrafish embryos; EC50 – the concentration with a negative
effect on the development of 50% of the zebrafish embryos (mortality
and teratogenicity).
Fig. 7 Effects of platinum(II) complexes (dmso-based: 1a, 3a and 5a in
comparison with pta-based: 1b, 3b and 5b) on the development of
zebrafish embryos: (A) at 0.5 to 10 µg mL−1 concentration at 96 hours
post fertilization (■ – normal embryos, – teratogenic embryos, and □
– lethal embryos) and (B) images of zebrafish embryos at 96 hpf
exposed to selected Pt(II) complexes. Depending on the type and con-
centration of platinum complexes, treated zebrafish embryos developed
pericardial edema (3b), skoliosis (1b and 3b), malformed jaw (5a) or
malformed notochord (5b).
Inorganic Chemistry Frontiers Research Article
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cancer cell lines, did not provoke significant in vivo toxic
response on the zebrafish embryo model at concentrations
close to IC50 values for certain cell lines (i.e. lung cancer),
making it promising for further development as a potential
therapeutic agent.
Experimental section
Materials and methods
Dimethyl sulfoxide (dmso), 1,3,5-triaza-7-phosphaadamantane
(pta), 5-chloro-7-iodo-8-quinolinol (clioquinol), 8-hydroxy-5-
nitroquinoline (nitroxoline), 5,7-dichloro-8-quinolinol, 5,7-
diiodo-8-quinolinol,5,7-dibromo-8-quinolinol, 5,7-dichloro-8-
hydroxy-2-methyl-quinoline, 8-hydroxyquinoline, 8-quinoline-
thiol, and K2[PtCl4] were obtained from Sigma-Aldrich. The
complex cis-[PtCl2(dmso)2] was synthesized according to the
published procedure.55
The NMR spectra were recorded on a Bruker Advance II 500
spectrometer (at room temperature and 500.1 MHz) by using
TMS as an internal standard. Infrared spectra were recorded
with a PerkinElmer Spectrum 100 FTIR spectrometer equipped
with a Specac Golden Gate Diamond ATR as a solid sample
support. UV–vis spectra were collected on a PerkinElmer
LAMBDA 750 UV/vis/near-IR spectrophotometer, while the
samples were prepared in chloroform with a concentration of
1 × 10−4 mol L−1. Elemental analyses for carbon, hydrogen and
nitrogen parameters were performed using a PerkinElmer 2400
II instrument. HRMS were recorded using an Agilent 6224
Accurate Mass TOF LC/MS instrument. X-ray diffraction data
were collected using an Oxford Diffraction SuperNova diffract-
ometer with a Mo or Cu microfocus X-ray source with mirror
optics and an Atlas detector. The structures were solved by
direct methods implemented in SIR9256 and refined by a full-
matrix least-squares procedure based on F2 using
SHELXL-97.57 All non-hydrogen atoms were refined anisotropi-
cally. The hydrogen atoms were placed at calculated positions
and treated using appropriate riding models. The programs
Mercury and Platon were used for data analysis and figure
preparation.58,59 Complete crystallographic data are given in
the ESI file in Tables S2 and S3.† The crystal structures of com-
pounds α-2a, β-2a, 6a, 1b, and 4b have been submitted to the
CCDC and have been allocated deposition numbers CCDC
1483253–1483257.†
Synthesis and characterization of Pt(II) complexes
Synthesis of [PtCl(hq)(dmso)] complexes (1a–8a). The plati-
num(II) complexes of the type [PtCl(hq)(dmso)] (where hq is
bidentately coordinated deprotonated 8-hydroxyquinoline or
8-quinolinethiol ligand) were synthesized by a slightly modi-
fied procedure published in the literature.16
0.25 mmol (105.56 mg) of cis-[PtCl2(dmso)2] were dissolved
in 15 mL of a 1 : 2 mixture of methanol and acetone. To this
solution were added 1.05 molar equivalents of the corres-
ponding hqH ligand and 1.2 molar equivalents of sodium
methoxide (acting as a base). The obtained mixture was stirred
at room temperature for 24 h. The solvent was then rotary
evaporated and the obtained solid product represented the
corresponding Pt(II) complex of sufficient purity with yields
between 70 and 80%. The purity of each Pt(II) complex (>98%)
was checked by elemental microanalysis, ESI-HRMS and NMR
spectroscopy.
[PtCl(5-chloro-7-iodo-8-hydroxyquinolinato)(S-dmso)] (1a).
Yield 78% (0.1116 g), yellow solid. 1H NMR (CDCl3,
500.10 MHz): δ 9.41 (dd, J = 5.3, 1.1 Hz, 1H, C2H), 8.59 (d, J =
1.2 Hz, 1H, C4H), 7.95 (s, 1H, C6H), 7.46 (dd, J = 8.5, 5.4 Hz,
1H, C3H), 3.68 (s, 6H, CH3-dmso). IR selected bands (cm
−1,
ATR): 3007, 1551, 1488, 1454, 1397, 1377, 1127, 1117, 1043,
1027, 805. UV–vis (λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4
mol L−1, CHCl3): 287 (33 000), 431 (4900). ESI-HRMS (CH3CN)
m/z (found for [M + H]+ (calc.)): 611.8550 (611.8453). Anal.
calc. for C11H10Cl2INO2PtS: C, 21.55; H, 1.64; N, 2.28. Found:
C, 21.11; H, 1.92; N, 1.96.
[PtCl(8-hydroxy-5-nitroquinolinato)(S-dmso)] (2a). Yield: 78%
(0.0923 g), yellow solid. The presence of two isomers is evident
in the NMR spectrum of 2a in CDCl3.
1H NMR (CDCl3,
500.10 MHz): δ 9.72 and 9.56 (2 × dd, J = 8.9, 1.1 Hz, J = 5.3,
1.2 Hz, 2 × 1H), 8.71 and 8.67 (2 × d, J = 9.1 Hz, J = 9.2 Hz,
2 × 1H), 7.82 and 7.75 (2 × dd, J = 8.9, 5.3 Hz, J = 9.0, 5.1 Hz,
2 × 1H), 7.18 and 7.08 (2 × d, J = 9.1 Hz, J = 9.1 Hz, 2 × 1H),
3.67 and 3.56 (s, 2 × 6H, CH3-dmso) ppm. IR selected bands
(cm−1, ATR): 3060, 3017, 1569, 1504, 1485, 1282, 1129, 817.
UV–vis (λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1, CHCl3):
286 (23 700), 328 (9800), 430 (12 000). ESI-HRMS (CH3CN) m/z
(found for [M + H]+ (calc.)): 496.9822 (496.9724). Anal. calc. for
C11H11ClN2O4PtS: C, 26.54; H, 2.23; N, 5.63. Found: C, 26.96;
H, 2.23; N, 5.58.
[PtCl(5,7-dichloro-8-hydroxyquinolinato)(S-dmso)] (3a). Yield:
69% (0.0841 g), yellow solid. 1H NMR (CDCl3, 500.10 MHz):
δ 9.50 (d, J = 4.5 Hz, 1H, C2H), 8.68 (d, J = 8.5 Hz, 1H, C4H),
7.69 (s, 1H, C6H), 7.53 (dd, J = 5.5, 5.5 Hz, 1H, C3H), 3.66 (s,
6H, CH3-dmso) ppm. IR selected bands (cm
−1, ATR): 3029,
3011, 1458, 1381, 1372, 1128, 1119, 1034, 890. UV–vis (λ (nm)
(ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1, CHCl3): 276 (39 000),
428 (5100). ESI-HRMS (CH3CN) m/z (found for [M + H]
+
(calc.)): 519.9194 (519.9097). Anal. calc. for C11H10Cl3NO2PtS:
C, 25.32; H, 1.93; N, 2.68. Found: C, 25.69; H, 1.93; N, 2.64.
[PtCl(5,7-diiodo-8-hydroxyquinolinato)(S-dmso)](4a). Yield:
75% (0.1231 g), yellow solid. 1H NMR (CDCl3, 500.10 MHz):
δ 9.33 (dd, J = 5.4, 1.1 Hz, 1H, C2H), 8.41 (dd, J = 8.5, 1.1 Hz,
1H, C4H), 8.32 (s, 1H, C6H), 7.40 (dd, J = 8.5, 5.4 Hz, 1H, C3H),
3.69 (s, 6H, CH3-dmso) ppm. IR selected bands (cm
−1, ATR):
3011, 1485, 1388, 1375, 1361, 1125, 1035. UV–vis (λ (nm)
(ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1, CHCl3): 290 (42 000),
353 (2200), 434 (6100). ESI-HRMS (CH3CN) m/z (found for
[M + H]+ (calc.)): 705.7933 (705.7932). Anal. calc. for
C11H10ClI2NO2PtS: C, 18.75; H, 1.43; N, 1.99. Found: C, 19.02;
H, 1.26; N, 1.98.
[PtCl(5,7-dibromo-8-hydroxyquinolinato)(S-dmso)] (5a). Yield:
78% (0.1304 g), yellow solid. 1H NMR (CDCl3, 500.10 MHz):
δ 9.49 (dd, J = 5.4, 1.1 Hz, 1H, C2H), 8.64 (dd, J = 8.5, 1.1 Hz,
1H, C4H), 8.00 (s, 1H, C6H), 7.54 (dd, J = 8.6, 5.4 Hz, 1H, C3H),
Research Article Inorganic Chemistry Frontiers
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3.69 (s, 6H, CH3-dmso) ppm. IR selected bands (cm
−1, ATR):
3087, 3022, 3002, 1495, 1454, 1370, 1126, 1117, 1030, 914, 871.
UV–vis (λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1, CHCl3):
278 (16 000), 347 (2100), 428 (4400). ESI-HRMS (CH3CN) m/z
(found for [M + H]+ (calc.)): 607.8181 (607.8082). Anal. calc. for
C11H10Br2ClNO2PtS: C, 21.64; H, 1.65; N, 2.29. Found: C,
21.97; H, 1.42; N, 2.18.
[PtCl(5,7-dichloro-8-hydroxy-2-methyl-quinolinato)(S-dmso)] (6a).
Yield: 80% (0.1179 g), yellow solid. 1H NMR (CDCl3,
500.10 MHz): δ 8.46 (d, J = 8.7 Hz, 1H), 7.53 (s, 1H), 7.32 (d, J =
8.7 Hz, 1H), 3.55 (s, 6H, CH3-dmso), 3.21 (s, 3H, CH3) ppm.
IR selected bands (cm−1, ATR): 3011, 1554, 1499, 1448, 1366,
1136, 1022, 969. UV–vis (λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4
mol L−1, CHCl3): 284 (35 000), 332 (2900), 433 (4900).
ESI-HRMS (CH3CN) m/z (found for [M + H]
+ (calc.)): 533.9353
(533.9250). Anal. calc. for C12H12Cl3NO2PtS: C, 26.90; H, 2.26;
N, 2.61. Found: C, 27.11; H, 2.21; N, 2.59.
[PtCl(8-hydroxyquinolinato)(S-dmso)] (7a). Yield: 79%
(0.0546 g), yellow solid. 1H NMR (CDCl3, 500.10 MHz): δ 9.40
(dd, J = 5.3, 1.2 Hz, 1H), 8.35 (dd, J = 8.3, 1.0 Hz, 1H),
7.52–7.41 (m, 2H), 7.07 (d, J = 8.0 Hz, 2H), 3.64 (s, 6H,
CH3-dmso) ppm. IR selected bands (cm
−1, ATR): 3014,
2916, 1504, 1470, 1382, 1320, 1122, 1112, 1033, 818. UV–vis
(λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1, CHCl3): 268
(38 000), 413 (4700). ESI-HRMS (CH3CN) m/z (found for
[M + H]+ (calc.)): 451.9955 (451.9857). Anal. calc. for
C11H12ClNO2PtS: C, 29.18; H, 2.67; N, 3.09. Found: C, 28.95; H,
2.29; N, 2.83.
[PtCl(8-quinolinethiolato)(S-dmso)] (8a). Yield: 71% (0.0435 g),
orange solid. 1H NMR (CDCl3, 500.10 MHz): δ 9.89 (dd, J = 5.4,
1.5 Hz, 1H), 8.39 (dd, J = 8.2, 1.4 Hz, 1H), 7.81 (dd, J = 7.4,
1.0 Hz, 1H), 7.58–7.54 (m, 2H), 7.49 (t, J = 7.7 Hz, 1H),
7.42–7.35 (m, 1H), 3.63 (s, 6H, CH3-dmso) ppm. IR selected
bands (cm−1, ATR): 3067, 3016, 2915, 1501, 1306, 1218, 1134,
1032, 984. UV–vis (λ (nm) (ε (L mol−1cm−1)) c = 1 × 10−4 mol
L−1, CHCl3): 265 (19 500), 479 (4100). ESI-HRMS (CH3CN) m/z
(found for [M + H]+ (calc.)): 469.9101 (469.9771). Anal. calc. for
C11H11ClNOPtS2: C, 28.12; H, 2.79; N, 2.98. Found: C, 28.03; H,
2.41; N, 3.03.
Synthesis of [PtCl(hq)(pta)] complexes (1b–8b). The corres-
ponding [PtCl(hq)(dmso)] complexes (1a–8a) (∼0.014 mmol)
were suspended in chloroform and 1.0 molar equivalent of
1,3,5-triaza-7-phosphaadamantane (pta) was added. The
obtained reaction mixture was heated at 40 °C for 1 h and after
that it was left stirring at room temperature for 24 h. The
solvent was then rotary evaporated and the obtained solid
product represents the corresponding Pt(II) complex.
Purification of all complexes was performed on a chromato-
graphic column with alumina as the stationary phase and a
mixture of acetone and dichloromethane as the eluent. The
column was first eluted with 3% and then 20% acetone in
dichloromethane.
[PtCl(5-chloro-7-iodo-8-hydroxyquinolinato)(pta)] (1b). Yield:
60% (0.0421 g), yellow solid. 1H NMR (CDCl3, 500.10 MHz):
δ 8.94–8.92 (m, 1H, C2H), 8.61 (dd, J = 8.6, 1.2 Hz, 1H, C4H),
7.85(s, 1H, C6H), 7.65 (ddd, J = 8.6, 4.9, 1.3 Hz, 1H, C3H), 4.59
(s, 6H, N–CH2–N), 4.46 (d, J = 2.1 Hz, 6H, N–CH2–P) ppm.
31P NMR (202 MHz, CDCl3): δ −61.56 ppm. IR selected bands
(cm−1, ATR): 2934, 2866, 1484, 1440, 1364, 1238, 1012, 966,
942. UV–vis (λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1,
CHCl3): 288 (27 000), 444 (4800). ESI-HRMS (CH3CN) m/z
(found for [M + H]+ (calc.)): 690.9179 (690.9082). Anal. calc. for
C15H16Cl2IN4OPPt: C, 26.03; H, 2.33; N, 8.09. Found: C, 25.74;
H, 2.58; N, 8.31.
[PtCl(8-hydroxy-5-nitroquinolinato)(pta)] (2b). Yield: 52%
(0.0349 g), yellow solid. 1H NMR (CDCl3, 500.10 MHz):
δ 8.91–8.89 (m, 2 × 1H), 8.46 (dd, J = 8.6, 1.2 Hz, 1H), 8.23 (s,
1H), 7.64–7.61 (m, 1H), 4.59 (s, 6H, N–CH2–N), 4.46 (d, J =
2.1 Hz, 6H, N–CH2–P).
31P NMR (202 MHz, CDCl3):
δ −61.41 ppm. IR selected bands (cm−1, ATR): 2922, 2853,
1568, 1504, 1482, 1454, 1295, 1277, 1236, 1008, 967, 943. UV–
vis (λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1, CHCl3): 270
(17 000), 333 (8100), 449 (12 400). ESI-HRMS (CH3CN) m/z
(found for [M + H]+ (calc.)): 579.0477 (579.0558). Anal. calc. for
C15H17ClN5O3PPt: C, 31.23; H, 2.97; N, 12.14. Found: C, 31.62;
H, 3.08; N, 12.45.
[PtCl(5,7-dichloro-8-hydroxyquinolinato)(pta)] (3b). Yield: 54%
(0.0485 g), yellow solid. 1H NMR (CDCl3, 500.10 MHz): δ 8.96
(dd, J = 6.5, 2.6 Hz, 1H, C2H), 8.62 (dd, J = 8.6, 1.2 Hz, 1H,
C4H), 7.63 (ddd, J = 8.6, 5.0, 1.3 Hz, 1H, C3H), 7.56 (s, 1H,
C6H), 4.59 (s, 6H, N–CH2–N), 4.45 (d, J = 1.9 Hz,6H, N–CH2–P)
ppm. 31P NMR (202 MHz, CDCl3): δ −62.27 ppm. IR selected
bands (cm−1, ATR): 2927, 2912, 1489, 1445, 1371, 1365, 1012,
972, 964, 942. UV–vis (λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4
mol L−1, CHCl3): 279 (40 500), 348 (2000), 441 (3700).
ESI-HRMS (CH3CN) m/z (found for [M + H]
+ (calc.)): 598.9827
(598.9726). Anal. calc. for C15H16Cl3N4OPPt: C, 29.99; H, 2.68;
N, 9.33. Found: C, 30.30; H, 2.87; N, 8.99.
[PtCl(5,7-diiodo-8-hydroxyquinolinato)(pta)] (4b). Yield: 52%
(0.0545 g), yellow solid. 1H NMR (CDCl3, 500.10 MHz):
δ 8.90–8.88 (m, 1H, C2H), 8.44 (dd, J = 8.6, 1.2 Hz, 1H, C4H),
8.22 (s, 1H, C6H), 7.62 (ddd, J = 8.6, 4.9, 1.4 Hz, 1H, C3H),
δ 4.60 (s, 6H, N–CH2–N), 4.47 (d, J = 2.0 Hz, 6H, N–CH2–P)
ppm. 31P NMR (202 MHz, CDCl3): δ −61.41 ppm. IR selected
bands (cm−1, ATR): 2930, 2908, 2861, 1478, 1440, 1358, 1014,
964, 941. UV–vis (λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1,
CHCl3): 290 (35 000), 445 (5600). ESI-HRMS (CH3CN) m/z
(found for [M + H]+ (calc.)): 781.8462 (781.8427). Anal. calc. for
C15H16ClI2N4OPPt: C, 22.99; H, 2.06; N, 7.15. Found: C, 23.21;
H, 1.87; N, 7.44.
[PtCl(5,7-dibromo-8-hydroxyquinolinato)(pta)] (5b). Yield: 55%
(0.0496 g), yellow solid. 1H NMR (CDCl3, 500.10 MHz):
δ 8.92–8.90 (m, 1H, C2H), 8.55 (d, J = 1.3 Hz, 1H, C4H), 7.83 (s,
1H, C6H), 7.64–7.61 (m, 1H, C3H), 4.59 (s, 6H, N–CH2–N), 4.46
(d, J = 2.1 Hz, 6H, N–CH2–P) ppm.
31P NMR (202 MHz, CDCl3):
δ −62.38 ppm. IR selected bands (cm−1, ATR): 2936, 2866,
1484, 1444, 1364, 1236, 1113, 1012, 965, 942. UV–vis (λ (nm)
(ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1, CHCl3): 283 (26 000),
349 (3300), 441 (6500). ESI-HRMS (CH3CN) m/z (found for
[M + H]+ (calc.)): 686.8805 (686.8706). Anal. calc. for
C15H16Br2ClN4OPPt: C, 26.12; H, 2.34; N, 8.13. Found: C,
26.34; H, 2.22; N, 7.99.
Inorganic Chemistry Frontiers Research Article
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[PtCl(5,7-dichloro-8-hydroxy-2-methyl-quinolinato)(pta)] (6b).
Yield: 58% (0.0421 g), yellow solid. 1H NMR (CDCl3,
500.10 MHz): δ 8.42 (d, J = 8.7 Hz, 1H), 7.47 (d, J = 3.4 Hz, 1H),
7.31 (dd, J = 8.7, 0.9 Hz, 1H), 4.56 (s, 6H, N–CH2–N), 4.49 (d,
J = 2.5 Hz, 6H, N–CH2–P) ppm.
31P NMR (202 MHz, CDCl3):
δ −64.10 ppm. IR selected bands (cm−1, ATR): 2914, 2870,
1551, 1444, 1425, 1365, 1277, 1239, 1011, 969, 943. UV–vis
(λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1, CHCl3): 284
(29 000), 350 (2000), 431 (5000). ESI-HRMS (CH3CN) m/z
(found for [M + H]+ (calc.)): 612.9967 (612.9866). Anal. calc. for
C16H18Cl3N4OPPt: C, 31.26; H, 2.95; N, 9.11. Found: C, 31.52;
H, 2.78; N, 8.88.
[PtCl(8-hydroxyquinolinato)(pta)] (7b). Yield: 54% (0.0406 g),
yellow solid. 1H NMR (CDCl3, 500.10 MHz): δ 9.41–9.40 (m,
1H), 8.35 (dd, J = 8.4, 1.2 Hz, 1H), 7.52–7.44 (m, J = 8.3, 4.9,
1.5 Hz, 2H), 7.07 (dd, J = 7.9, 3.3 Hz, 2H), 4.58 (s, 6H, N–CH2–
N), 4.45 (d, J = 1.9 Hz, 6H, N–CH2–P) ppm.
31P NMR (202 MHz,
CDCl3): δ −63.58 ppm.IR selected bands (cm−1, ATR): 2932,
2871, 1500, 1464, 1375, 1319, 1277, 1240, 1011, 970, 944. UV–
vis (λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4 mol L−1, CHCl3): 273
(22 000), 426 (4000). ESI-HRMS (CH3CN) m/z (found for
[M + H]+ (calc.)): 532.0471 (532.0441). Anal. calc. for
C15H18ClN4OPPt: C, 33.87; H, 3.41; N, 10.54. Found: C, 33.45;
H, 3.28; N, 10.47.
[PtCl(8-quinolinethiolato)(pta)] (8b). Yield: 51% (0.0400 g),
orange solid. 1H NMR (CDCl3, 500.10 MHz): δ 9.83–9.81 (m,
1H), 8.37 (dd, J = 8.2, 1.2 Hz, 1H), 7.81 (d, J = 7.3 Hz, 1H),
7.62–7.59 (m, 1H), 7.45 (t, J = 7.7 Hz, 1H), 7.38 (d, J = 7.8 Hz,
1H), 4.55 (s, 6H, N–CH2–N), 4.42 (d, J = 1.9 Hz, 6H, N–CH2–P)
ppm. 31P NMR (202 MHz, CDCl3): δ −61.85 ppm. IR selected
bands (cm−1, ATR): 3046, 2914, 2867, 1497, 1275, 1238, 1218,
1011, 969, 944. UV–vis (λ (nm) (ε (L mol−1 cm−1)) c = 1 × 10−4
mol L−1, CHCl3): 272 (21 000), 464 (4700). ESI-HRMS (CH3CN)
m/z (found for [M + H]+ (calc.)): 545.0412 (545.0269). Anal.
calc. for C15H18ClN4SPPt: C, 32.82; H, 3.49; N, 10.21. Found: C,
33.20; H, 3.29; N, 9.85.
Reactivity of complexes towards the DNA model compound
5′-guanosine monophosphate
Compounds 1a and 1b (2–3 mg) were dissolved in 630 µL of
dmso-d6. An equimolar amount of 5′-GMP disodium salt was
dissolved in approx. 70 µL of D2O and added to the NMR tube
containing the solution of a complex. 1H NMR spectra were
recorded prior to the addition of 5′-GMP and after 5/10 min
(1a/1b), 20, 45, 75 min, 3, 5, 24, 72 h, and 1 week.
Cell viability assays
Cell viability was tested by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) colorimetric assay as pre-
viously described.60 Assays were carried out after 48 h of cell
incubation in media containing test compounds at concen-
trations ranging from 0.1 µg mL−1 to 10 µg mL−1. Compounds
were used from the stock solutions freshly prepared in dmso.
The results are presented as percentage of the control (cells
treated with dmso) that was arbitrarily set to 100%. The per-
centage viability values were plotted against the log of concen-
tration and a sigmoidal dose response curve was calculated by
non-linear regression analysis using GraphPad Prism software
version 5.0 for Windows (GraphPad Software, CA, USA). From
these curves, IC50 values were obtained.
Platinum cellular uptake assay
The Pt content was measured using inductively coupled
plasma mass spectrometry (ICP-MS) according to a previously
published procedure61 but with minor modifications. A549
cells (6 × 105 per plate) were seeded into 60 mm plates in a
total volume of 5 ml of RPMI medium per plate, cultured for
24 h, and then exposed to 2 μM of the investigated compounds
for 2 h at 37 °C. The degree of confluence in the case of A549
cells at the end of exposure was nearly 80%. After exposure,
the compound-containing medium was removed, and the cells
were washed with 5 ml PBS and then lysed in 1.12 mL of sub-
boiled nitric acids for 1.5 h at room temperature. After this
period, an aliquot of 0.28 ml was transferred into a 10 mL tube
and after adding the internal standards, diluted with Milli-Q
water.
The measurements of Pt in samples were carried out on an
ICP-MS (iCAP Q, Thermo Scientific X series 2, UK). A platinum
stock solution containing 1.000 g L−1 of this element was used
to prepare standard solutions for the ICP-MS measurements.
As internal standards were used the following: 6Li, 45Sc, 115In
and 159Tb (VHG standards, Manchester, UK). The system was
controlled using Qtegra Instrument Control software.
Instrument conditions for the determinations are given in
Table S4.† Each sample was analyzed in triplicate and each
analysis consisted of three replicates. The coefficients of vari-
ation for single measurements were below 10%.
In vitro DNA binding by gel electrophoresis assay
Genomic DNA (gDNA) from Pseudomonas aeruginosa PAO1 was
purified with a DNeasy tissue kit (Qiagen, Hilden, Germany)
and it was used as model for high molecular weight double
stranded DNA. The quality and the concentration of DNA were
estimated by measuring UV absorbance with a NanoVue Plus
spectrophotometer (GE Healthcare, Freiburg, Germany). The
ability of the used Pt(II) complexes and cisplatin to bind gDNA
from P. aeruginosa was examined by agarose gel electrophoresis
as previously described.62 Briefly, for the gel electrophoresis
experiments, gDNA (500 ng) was treated with the tested com-
pounds (25 µg mL−1) in phosphate buffer (pH 7.4), and the
contents were incubated for 12 h at 37 °C, then subjected to
gel electrophoresis on 0.8% (w/v) agarose gel containing
0.1 µg mL−1 of ethidium bromide in TAE buffer (40 mM Tris
acetate/1 mM EDTA, pH 7.4) buffer at 60 V for 2 h. Gels were
visualized and analyzed using a Gel Doc EZ system (Bio-Rad,
Life Sciences, Hercules, USA) equipped with the Image Lab™
software.
Molecular docking
For in silico analysis of DNA–metal complex interactions, the
semi-empirical quantum chemistry method (PM6) was applied
for the geometry optimization of the studied Pt(II) complexes.63
Research Article Inorganic Chemistry Frontiers
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The PM6 method was chosen because of its excellent compro-
mise between computational time and description of elec-
tronic correlation.64 This semi-empirical level of theory has
already been successfully applied to metal complex geometry
optimization in similar docking studies.65,66 All geometry
optimization calculations were performed using the Gaussian
09 molecular package.67 As a model to study the interaction
between the metal complex and DNA the structure of the
B-DNA dodecamer d(CGCGAATTCGCG)2 (PDB:1BNA) was
used.68 The flexible compound structures were docked into
rigid DNA structures using the Molegro Virtual Docker (MVD
v. 2013.6.0.1).69 MVD has been successfully applied in docking
studies of metal complexes in DNA.65,70 Hydrogen bonds, and
hydrophilic and hydrophobic interactions between the studied
complexes and DNA were calculated. The binding site was
computed with a grid resolution of 0.3 Å. The MolDock SE as a
search algorithm was used with the number of runs set at 100.
The parameters of the docking procedure were: population
size 50, maximum number of iterations 1500, energy threshold
100.00 and maximum number of steps 300. The number of
generated poses was 5. The estimation of Pt(II) complexes and
DNA interactions was described by the MVD-related scoring
functions: MolDock Score, Docking Score, Rerank Score,
Hbond Score, van der Waals (VdW) and van der Waals
(Hbond) Score in relation to DNA interaction, Steric inter-
actions and Ligand efficiency (LE1 and LE3). A maximum
population of 100 and a maximum number of iterations of
10 000 were used for each run and the best five poses were
retained. Visualization of the docked pose has been done by
using the CHIMERA (http://www.cgl.ucsf.edu/chimera/) mole-
cular graphics program.
Toxicity against zebrafish embryos
Zebrafish embryo-toxicity assessments were carried out accord-
ing to general rules of the OECD Guidelines for the Testing of
Chemicals.71 All experiments involving zebrafish were per-
formed in compliance with the European directive 86/609/EEC
and the ethical guidelines of the Guide for the Care and Use of
Laboratory Animals of the Institute for Molecular Genetics and
Genetic Engineering, University of Belgrade.
Adult wild type zebrafish (Danio rerio) obtained from a com-
mercial supplier (Pet Centar, Belgrade, Serbia) and maintained
under laboratory conditions for several months were used in
this study. A preliminary embryotoxicity screen was carried out
using eight different Pt(II) complexes (1a, 1b, 3a, 3b, 5a, 5b, 6a,
and 6b) at three different concentrations (1, 2.5 and 10
µg mL−1) using 20 embryos per concentration. Based on the
results of this screen, LC50 and EC50 values were determined
for 6 different Pt(II) complexes (1a, 1b, 3a, 3b, 5a, and 5b)
testing 7 different concentrations (0.5, 1, 1.5, 2, 2.5, 5 and
10 µg mL−1) and 30 embryos per concentration. Embryos were
treated at 4 hours post fertilization (hpf) with seven concen-
trations of Pt(II) complexes (0.5, 1, 1.5, 2, 2.5, 5 and 10
µg mL−1) using 30 embryos per concentration. dmso (0.1%,
v/v) was used as a negative control. Embryos were placed to
24-well plates containing 1000 μL test solution, 10 embryos
per well, and incubated at 28 °C.
All embryos were staged and evaluated using standard
procedures as previously described.71,72 Apical endpoints
(Table S5†) were recorded at 24, 48, 72, 96 and 114 h post ferti-
lization (hpf) using an inverted microscope (CKX41; Olympus,
Tokyo, Japan). Based on the results of this assay, LC50 and
EC50 values were determined.
The evaluation of ROS production in the zebrafish model
Generation of intracellular ROS in zebrafish embryos upon
Pt-complex treatments was determined by using an oxidation-
sensitive fluorescent probe dye, 2′,7′-dichlorodihydrofluo-
rescein diacetate (DCF-DA), as described previously.73 Briefly,
embryos were exposed to different concentrations of the tested
compounds in a period of 6–72 hpf; afterwards embryos were
treated with a DCFH-DA solution (20 µg mL−1) and incubated
for 1 h in the dark at 28.5 °C. After incubation, the embryos
were rinsed in fresh embryo water and anesthetized before
visualization. The images of stained embryos were observed
using a fluorescent microscope (Olympus BX51, Applied
Imaging Corp., San Jose, CA, USA) and the fluorescence inten-
sity of individual larvae was quantified using the Image
J program.
DNA fragmentation assessment
For the analysis of cellular DNA degradation, A495 cells
(2 × 105 cells) were exposed to concentrations equal to the IC50
of cisplatin and selected Pt(II) complexes (1a, 1b, 3a, 3b, 5a,
and 5b) for 48 h. The DNA was subsequently extracted from
the cells and analyzed by agarose electrophoresis (1%, w/v,
agarose gel in a TAE buffer (40 mM Tris acetate/1 mM EDTA,
pH 7.4) at 60 V for 2 h) as described previously.74
To examine the effect of the platinum complex on zebrafish
cellular DNA, a total of ten zebrafish embryos have been
exposed to LC50 concentrations (the concentration causing the
mortality of 50% of the embryos; Table 5) of six platinum com-
plexes (1a, 1b, 3a, 3b, 5a, and 5b) for 48 h (from 6 to 54 hpf).
Cisplatin was used as a positive control at a concentration of
10 µg mL−1. The DNA was subsequently extracted from the
zebrafish embryos using a DNeasy Blood and Tissue kit
(Qiagen, Hilden, Germany) according to the manufacturer’s
instructions and analyzed by agarose electrophoresis (0.8%,
w/v, agarose gel in a TAE buffer (40 mM Tris acetate/1 mM
EDTA, pH 7.4) at 70 V for 30 min).
Conclusions
Anticancer platinum complexes with their unique physico-
chemical properties still prevail in the field of metals in cancer
chemotherapy with their use escalated and being sustained
over decades.75 Although a huge number of studies have been
performed with various platinum compounds (including cis-
platin) in the last five decades, there are still many questions
that are unsolved. It is therefore extremely important to bring
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new insights into this field not only to better understand old
drugs but also to design new potential drugs more success-
fully. The sixteen complexes assessed in this study exhibited
different effects and activity in comparison with cisplatin.
Evidence is shown that DNA is not the main target of the plati-
num-hq complexes but further work is needed to elucidate
their exact mode of action. On the other side, pta containing
Pt(II) complexes showed greater potential in terms of selectivity
towards cancer cells, a mode-of-action which involves
increased ROS generation and better embryotoxic profile in
comparison with dmso containing counterparts, with [PtCl
(5,7-dibromo-8-hydroxyquinolinato)(pta)] (5b) being the most
promising complex from this study.
Conflicts of interest
There are no conflicts to declare.
Acknowledgements
This work has been financially supported by the Ministry of
Education and Science, Republic of Serbia, under Grant No.
172036 and 173048 and the programme grant P1-0175 (I. T.)
and the postdoctoral research grant Z1-6735 (to J. K.) from the
Slovenian Research Agency. The EN→FIST Centre of
Excellence, Trg OF 13, SI-1000 Ljubljana, Slovenia, is acknow-
ledged for the use of a SuperNova diffractometer. M. Ž. is
grateful to the Erasmus Mundus Action 2 Project Basileus
V for a scholarship for post-docs with 6 months mobility
period at the University of Ljubljana. Great gratitude also goes
to the support from the bilateral Slovenian–Serbian project
BI-RS/16-17-024.
References
1 B. Rosenberg, L. Vancamp, J. E. Trosko and V. H. Mansour,
Nature, 1969, 222, 385.
2 N. Muhammad and Z. Guo, Curr. Opin. Chem. Biol., 2014,
19, 144.
3 B. Rosenberg, in Cisplatin: Chemistry and Biochemistry of a
Leading Anticancer Drug, ed. B. Lippert, Wiley-VCH,
New York, 1999, pp. 3–30.
4 Z. Siddik, Oncogene, 2003, 22, 7265.
5 M. A. Fuertes, C. Alonso and J. M. Pérez, Chem. Rev., 2003,
103, 645.
6 G. Chu, J. Biol. Chem., 1994, 269, 787.
7 L. R. Kelland, Drugs, 2000, 59, 37.
8 N. Farrell, Compr. Coord. Chem. II, 2003, 9, 809.
9 L. Kelland, Nat. Rev. Cancer, 2007, 7, 573.
10 Y. Jung and S. J. Lippard, Chem. Rev., 2007, 107, 1387.
11 D. Wang and S. J. Lippard, Nat. Rev. Drug Discovery, 2005, 4,
307.
12 X. Wang, Anti-Cancer Agents Med. Chem., 2010, 10, 396.
13 N. J. Wheate and J. G. Collins, Curr. Med. Chem.: Anti-
Cancer Agents, 2005, 5, 267.
14 N. J. Wheate, S. Walker, G. E. Craig and R. Oun, Dalton
Trans., 2010, 39, 8113.
15 J. Zhang, L. Wang, Z. Xing, D. Liu, J. Sun, X. Li and
Y. Zhang, Anti-Cancer Agents Med. Chem., 2010, 10, 272.
16 C. M. Santos, S. Cabrera, C. Ríos-Luci, J. M. Padrón,
I. L. Solera, A. G. Quiroga, M. A. Medrano, C. Navarro-
Ranninger and J. Alemán, Dalton Trans., 2013, 42, 13343
and references cited therein.
17 K. G. Daniel, D. Chen, S. Orlu, Q. C. Cui, F. R. Miller and
Q. P. Dou, Breast Cancer Res., 2005, 7, R897.
18 X. Mao, X. Li, R. Sprangers, X. Wang, A. Venugopal,
T. Wood, Y. Zhang, D. A. Kuntz, E. Coe, S. Trudel, D. Rose,
R. A. Batey, L. E. Kay and A. D. Schimmer, Leukemia, 2009,
23, 585.
19 V. Prachayasittikul, S. Prachayasittikul, S. Ruchirawat and
V. Prachayasittikul, Drug Des., Dev. Ther., 2013, 7, 1157.
20 M. Gobec, J. Kljun, I. Sosič, I. Mlinarič-Raščan, M. Uršič,
S. Gobec and I. Turel, Dalton Trans., 2014, 43, 9045.
21 A. Mitrović, J. Kljun, I. Sosič, S. Gobec, I. Turel and J. Kos,
Dalton Trans., 2016, 45, 16913.
22 B. Murugasu-Oei and T. Dick, Int. J. Antimicrob. Agents,
2001, 18, 579.
23 B. Mirković, M. Renko, S. Turk, I. Sosič, Z. Jevnikar,
N. Obermajer, D. Turk, S. Gobec and J. Kos,
ChemMedChem, 2011, 6, 1351.
24 B. Mirković, B. Markelc, M. Butinar, A. Mitrović, I. Sosič,
S. Gobec, O. Vasiljeva, B. Turk, M. Čemažar, G. Serša and
J. Kos, Oncotarget, 2015, 6(22), 19027.
25 I. Sosič, B. Mirković, K. Arenz, B. Štefane, J. Kos and
S. Gobec, J. Med. Chem., 2013, 56(2), 521.
26 A. D. Phillips, L. Gonsalvi, A. Romerosa, F. Vizza and
M. Peruzzini, Coord. Chem. Rev., 2004, 248, 955.
27 B. S. Murray, M. V. Babak, C. G. Hartinger and P. J. Dyson,
Coord. Chem. Rev., 2016, 306, 86 and references cited
therein.
28 A. D. Phillips, L. Gonsalvi, A. Romerosa, F. Vizza and
M. Peruzzini, Coord. Chem. Rev., 2004, 248, 955.
29 J. Bravo, S. Bolaño, L. Gonsalvi and M. Peruzzini, Coord.
Chem. Rev., 2010, 254, 555.
30 K. S. O. Ferraza, D. C. Reisa, J. G. Da Silvaa, E. M. Souza-
Fagundesb, E. J. Baranc and H. Beraldo, Polyhedron, 2013,
63, 28.
31 A. Casado-Sánchez, R. Gómez-Ballesteros, F. Tato,
F. J. Soriano, G. Pascual-Coca, S. Cabrera and J. Alemán,
Chem. Commun., 2016, 52, 9137.
32 T. Meng, S.-F. Tang, Q.-P. Qin, Y.-L. Liang, C.-X. Wu,
C.-Y. Wang, H.-T. Yan, J.-X. Donga and Y.-C. Liu,
MedChemComm, 2016, 7, 1802.
33 M. Kato, Y. Ogawa, M. Kozakai and Y. Sugimoto, Acta
Crystallogr., Sect. C: Cryst. Struct. Commun., 2002, 58, m147.
34 L. Yang, D. R. Powella and R. P. Houser, Dalton Trans.,
2007, 955.
35 A. Okuniewski, D. Rosiak, J. Chojnacki and B. Becker,
Polyhedron, 2015, 90, 47.
Research Article Inorganic Chemistry Frontiers
52 | Inorg. Chem. Front., 2018, 5, 39–53 This journal is © the Partner Organisations 2018
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
O
ct
ob
er
 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
1/
17
/2
01
8 
11
:0
1:
16
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
36 S. J. Fischer, L. M. Benson, A. Fauq, S. Naylor and
A. J. Windebank, Neurotoxicology, 2008, 29, 444.
37 S. P. Wisnovsky, J. J. Wilson, R. J. Radford, M. P. Pereira,
M. R. Chan, R. R. Laposa, S. J. Lippard and S. O. Kelley,
Chem. Biol., 2013, 20(11), 1323.
38 J. Reedijk, Proc. Natl. Acad. Sci. U. S. A., 2003, 100, 3611.
39 I. Turel and J. Kljun, Curr. Top. Med. Chem., 2011, 11(21),
2661.
40 R. C. Todd and S. J. Lippard, Metallomics, 2009, 1, 280.
41 Y. Jung and S. J. Lippard, Chem. Rev., 2007, 107, 1387;
Y. Zhao, W. He, P. Shi, J. Zhu, L. Qiu, L. Lin and Z. Guo,
Dalton Trans., 2006, 2617.
42 H. P. Varbanov, D. Ortiz, D. Höfer, L. Menin, M. Galanski,
B. K. Keppler and P. J. Dyson, Dalton Trans., 2017, 46, 8929.
43 N. Raman, S. Sobha and L. Mitu, Monatsh. Chem., 2012,
143, 1019; Q. Saquib, A. A. Al-Khedhairy, S. A. Alarifi,
S. Dutta, S. Dasgupta and J. Musarrat, Int. J. Biol.
Macromol., 2010, 47, 68.
44 R. Filosa, A. Peduto, S. Di Micco, P. de Caprariis, M. Festa,
A. Petrella, G. Capranico and G. Bifulco, Bioorg. Med.
Chem., 2009, 17, 13.
45 M. A. Fuertes, C. Alonso and J. M. Pérez, Chem. Rev., 2003,
103(3), 645.
46 S. E. Miller and D. A. House, Inorg. Chim. Acta, 1991, 187,
125.
47 X. L. Yang and A. H. Wang, Pharmacol. Ther., 1999, 83, 181.
48 V. Cepeda, M. A. Fuertes, J. Castilla, C. Alonso, C. Quevedo
and J. M. Pérez, Anticancer Agents Med. Chem., 2007, 7, 3.
49 S. Kemp, N. J. Wheate, D. P. Buck, M. Nikac, J. G. Collins
and J. R. Aldrich-Wright, J. Inorg. Biochem., 2007, 101, 1049.
50 S. Kemp, N. J. Wheate, M. J. Pisani and J. R. Aldrich-
Wright, J. Med. Chem., 2008, 51(9), 2787.
51 R. Osterauer, N. Haus, B. Sures and H. R. Köhler,
Chemosphere, 2009, 975.
52 P. V. Asharani, Y. Lianwu, Z. Gong and S. Valiyaveettil,
Nanotoxicol., 2011, 43.
53 R. S. Go and A. A. Adjei, J. Clin. Oncol., 1999, 17, 409.
54 Y. Hirose, J. A. Simon and H. C. Ou, J. Assoc. Res.
Otolaryngol., 2011, 12, 719.
55 J. H. Price, A. N. Williamson, R. F. Schramm and
B. B. Wayland, Inorg. Chem., 1972, 11, 1280.
56 A. Altomare, G. Cascarano, C. Giacovazzo, A. C. Guagliardi,
M. C. Burla, G. Polidori and M. Camalli, J. Appl.
Crystallogr., 1994, 27, 435.
57 G. M. Sheldrick, Acta Crystallogr., Sect. A: Fundam.
Crystallogr., 2008, 64, 112.
58 A. L. Spek, Acta Crystallogr., Sect. D: Biol. Crystallogr., 2009,
65, 148.
59 C. F. Macrae, P. R. Edgington, P. McCabe, E. Pidcock,
G. P. Shields, R. Taylor, M. Towler and J. van De Streek,
J. Appl. Crystallogr., 2006, 39, 453.
60 M. B. Hansen, S. E. Nielsen and K. Berg, J. Immunol.
Methods, 1989, 119, 203.
61 A. E. Egger, C. Rappel, M. A. Jakupec, C. G. Hartinger,
P. Heffeter and B. K. Keppler, J. Anal. At. Spectrom., 2009,
24, 51.
62 V. T. Yilmaz, E. Gocmen, C. Icsel, M. Cengiz, S. Y. Susluer
and O. Buyukgungor, J. Photochem. Photobiol., B, 2014, 131,
31.
63 E. A. Amin and D. G. Truhlar, J. Chem. Theory Comput.,
2008, 4, 75; J. J. P. Stewart, J. Mol. Model, 2007, 13, 1173.
64 G. Frison and G. Ohanessian, J. Comput. Chem., 2008, 29, 416.
65 L. Senerovic, M. D. Zivkovic, A. Veselinovic, A. Pavic,
M. I. Djuran, S. Rajkovic and J. Nikodinovic-Runic, J. Med.
Chem., 2015, 58, 1442.
66 A. M. A. Alaghaz, B. A. El-Sayed, A. A. El-Henawy and
R. A. A. Ammar, J. Mol. Struct., 2013, 1035, 83; R. Cincinelli,
L. Musso, S. Dallavalle, R. Artali, S. Tinelli, D. Colangelo,
F. Zunino, M. De Cesare, G. L. Beretta and N. Zaffaroni,
Eur. J. Med. Chem., 2013, 63, 387.
67 M. J. Frisch, Gaussian 09, Wallingford, CT, 2004.
68 H. R. Drew, R. M. Wing, T. Takano, C. Broka, S. Tanaka,
K. Itakura and R. E. Dickerson, Proc. Natl. Acad. Sci.
U. S. A., 1981, 78, 2179; K. Suntharalingam, O. Mendoza,
A. A. Duarte, D. J. Mann and R. Vilar, Metallomics, 2013, 5,
514.
69 R. Thomsen and M. H. Christensen, J. Med. Chem., 2006,
49, 3315.
70 A. A. Adeniyi and P. A. Ajibade, Molecules, 2013, 18, 10829.
71 OECD guidelines for the testing of chemicals, Fish embryo
acute toxicity (FET) test. OECD 2013, No 236.
72 C. B. Kimmel, W. W. Ballard, S. R. Kimmel, B. Ullmann
and T. F. Schilling, Dev. Dyn., 1995, 203, 253.
73 E. A. Kim, S. H. Lee, C. I. Ko, S. H. Cha, M. C. Kang,
S. M. Kang, S. C. Ko, W. W. Lee, J. Y. Ko, J. H. Lee, N. Kang,
J. Y. Oh, G. Ahn, Y. H. Jee and Y. J. Jeon, Carbohydr. Polym.,
2014, 102, 185.
74 G. V. Kalayda, S. Komeda, K. Ikeda, T. Sato, M. Chikuma
and J. Reedijk, Eur. J. Inorg. Chem., 2003, 4347.
75 G. Sava, A. Bergamo and P. Dyson, Dalton Trans., 2011, 40,
9069; J. Zhang, L. Wang, Z. Xing, D. Liu, J. Sun, X. Li and
Y. Zhang, Anticancer Agents Med. Chem., 2010, 10, 272.
Inorganic Chemistry Frontiers Research Article
This journal is © the Partner Organisations 2018 Inorg. Chem. Front., 2018, 5, 39–53 | 53
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
O
ct
ob
er
 2
01
7.
 D
ow
nl
oa
de
d 
on
 1
1/
17
/2
01
8 
11
:0
1:
16
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
